TREE NEWS update: Eisai’s Alzheimer’s drug lecanemab (Leqembi) has been approved in China for subcutaneous auto-injector use, enabling at-home initial treatment for early-stage Alzheimer’s. The National Medical Products Administration granted approval, making China the second country globally and the first in Asia to allow the device, following US approval in July.
China approves subcutaneous auto-injector for Alzheimer’s drug Leqembi
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
44m ago
China’s weather agency issues typhoon blue alert for Typhoon Koron
48m ago
BYD Exec: No Discounts, We Export Technology
52m ago
Nine Yangtze Delta Cities Issue Joint Low-Altitude Safety Initiative
1h ago
US President’s Envoys Arrive in Moscow
1h ago
China NDRC Allocates 20M Yuan for Jiangxi Flood Recovery
1h ago
Shenzhen new home sales fall 23% m/m in August